ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling Summary This study explores the predictive power of the Immune Cell-Associated Neurotoxicity Syndrome (ICANS) risk model in CD19 CAR-T therapy patients Read More
Tags :Medicine/Public Health
Education, Research & Positions
Endogenous T cell responses to fusion-derived neoantigens in pediatric acute
Endogenous T cell responses to fusion-derived neoantigens in pediatric acute leukemias Summary Pediatric acute leukemias, particularly those with fusion oncogenes, can generate unique neoantigens derived from the fusion point. Research has shown that the immune Read More
Education, Research & Positions
Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma
Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma Summary A study reveals that Bifidobacterium species enhance the efficacy of anti-PD-1 immunotherapy in hepatocellular carcinoma (HCC). The mechanism involves Bifidobacterium modulating the gut microbiome, Read More
Education, Research & Positions
Immunological features of clear-cell renal-cell carcinoma and resistance to immune
Immunological features of clear-cell renal-cell carcinoma and resistance to immune checkpoint inhibitors Summary Clear-cell renal cell carcinoma (ccRCC) is characterized by immune infiltration, but often exhibits resistance to immune checkpoint inhibitors (ICIs). Several factors contribute Read More
Education, Research & Positions
Immunotherapy for diffuse gastric cancer: challenges and new avenues –
Immunotherapy for diffuse gastric cancer: challenges and new avenues Summary Immunotherapy offers promise for treating diffuse gastric cancer (DGC), a particularly aggressive subtype with limited therapeutic options. However, DGC presents unique challenges, including low immunogenicity Read More
Education, Research & Positions
The microbiota in radiotherapy-induced cancer immunosurveillance – New Study
The microbiota in radiotherapy-induced cancer immunosurveillance Summary Radiotherapy (RT) can trigger anti-tumor immune responses, a process known as immunosurveillance. The gut microbiota plays a crucial role in modulating this process. RT-induced changes in the gut Read More
Education, Research & Positions
Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with
Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study Summary This phase II study explored the efficacy of adding sintilimab (an anti-PD-1 immunotherapy) Read More
Education, Research & Positions
Therapeutic targeting of mismatch repair-deficient cancers – New Study
Therapeutic targeting of mismatch repair-deficient cancers Summary Mismatch repair deficient (dMMR) cancers, characterized by high microsatellite instability (MSI-H), represent a distinct subset with unique vulnerabilities. Lacking proper DNA repair mechanisms, they accumulate mutations, leading to Read More
Education, Research & Positions
A new first-line option for advanced-stage anal squamous cell carcinoma
A new first-line option for advanced-stage anal squamous cell carcinoma Summary A novel drug combination of chemotherapy (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab has emerged as a promising new first-line treatment for advanced-stage Read More
Education, Research & Positions
Perioperative pembrolizumab demonstrates clinical benefit in locally advanced HNSCC
Perioperative pembrolizumab demonstrates clinical benefit in locally advanced HNSCC Summary Perioperative pembrolizumab, combining neoadjuvant and adjuvant immunotherapy around surgery, shows promising clinical benefit in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Read More
Site Logo
Powered by AI
New Journal Citation Reports (JCR) 2025
All-Time Views
1 Million+ Views and Counting..!
Follow me on Linkedin for Latest Jobs and Scholarships
Subscribe Youtube
Celebrating 7 Years
It has been 7 years since it was launched in late July 2018, and it is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
Site Trust Score
Google Safe
